循环Pre-S/S准种是否影响HBeAg阴性期HBV感染者HBsAg水平
研究纳入260例未经治疗、HBeAg阴性、D基因型HBsAg携带者,按HBV-DNA水平分为HBeAg阴性感染、灰区、慢性肝炎和肝硬化组,采用群体测序检测Pre-S/S基因突变。结果显示Pre-S/S异质性随肝病严重程度增加,但不影响HBsAg血清水平;低病毒血症携带者的HBsAg水平与HBV有效控制相关。
要点
- Pre-S/S突变在肝硬化组占60.0%,慢性肝炎组31.7%,HBeAg阴性感染组7.0%,灰区组7.1%。
- 有突变者总体HBsAg水平较高,但按感染阶段分层后无显著差异。
- 感染阶段、年龄、ALT、肝硬度和HBV-DNA独立关联HBsAg水平,M-mut未显示独立关联。
核心结论
- 在HBeAg阴性、D基因型携带者中,Pre-S/S异质性随肝病严重程度增加,但不影响HBsAg血清水平。
- 低病毒血症携带者的HBsAg水平与HBV有效控制相关。
研究设计与样本
- 研究纳入260例未经治疗的HBeAg阴性、D基因型HBsAg携带者。
- 分组:71例HBeAg阴性感染(HBV-DNA ≤2000 IU/mL),42例灰区(HBV-DNA ≤20 000 IU/mL),82例慢性肝炎和65例肝硬化(HBV-DNA > 20 000 IU/mL)。
- 采用群体测序鉴定Pre-S/S基因中导致氨基酸替换或潜在生物学/抗原性影响的突变(M-muts)。
主要发现
- HBsAg血清水平在HBeAg阴性感染+灰区组低于慢性肝炎+肝硬化组(2.61 vs 3.62 log10 IU/mL,P < 0.001)。
- HBsAg血清水平在肝硬化组低于慢性肝炎组(3.48 vs 3.66 log10 IU/mL,P < 0.001)。
- M-muts见于73例(28.1%):HBeAg阴性感染组5例(7.0%)、灰区组3例(7.1%)、慢性肝炎组26例(31.7%)、肝硬化组39例(60.0%)(P < 0.001)。
- M-muts主要位于Pre-S2(17.6%),高于Pre-S1(5.8%)和小S(10.8%)(P < 0.001)。
- 总体上有M-muts的携带者HBsAg血清水平高于无M-muts者(3.56 vs 3.17 log10 IU/mL,P < 0.001),但分别分析时,HBeAg阴性感染+灰区组(2.84 vs 2.61 log10 IU/mL,P = 0.330)和慢性肝炎+肝硬化组(3.57 vs 3.63 log10 IU/mL,P = 0.37)中均无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Virus, host factors and their interplay influence Hepatitis B surface Antigen serum levels during Hepatitis B Virus (HBV) infection course and treatment. AIM: To study the Pre-S/S circulating quasispecies in a cohort of untreated, HBeAg negative, genotype-D, HBsAg carriers. METHODS: We studied 260 carriers: 71 with HBeAg negative infection (ENI; HBV-DNA ≤2000 IU/mL); 42 Grey Zone (GZ; HBV-DNA ≤20 000 IU/mL); 82 chronic hepatitis (CH) and 65 cirrhosis (CI) (HBV-DNA > 20 000 IU/mL). Population sequencing was applied to identify Pre-S/S gene mutations responsible for any amino acid substitution or potential biological/antigenic implications (M-muts) on HBsAg. RESULTS: HBsAg serum levels were lower in ENI + GZ than in CH + CI (2.61 [-1.10/4.06] vs 3.62 [2.41/4.92] log10 IU/mL, P < 0.001) and in CI than CH (3.48 [2.41/4.38] vs 3.66 [2.57/4.92] log10 IU/mL, P < 0.001). M-muts were found in 73 (28.1%) cases: 5 (7.0%) ENI, 3 (7.1%) GZ, 26 (31.7%) CH, 39 (60.0%) CI (P < 0.001) and mostly in Pre-S2 (17.6%) than Pre-S1 (5.8%) and Small-S (10.8%; P < 0.001). Overall HBsAg serum levels were higher in carriers with M-muts (3.56 [0.95/4.38] vs 3.17 [-1.10/4.92] log10 IU/mL, P < 0.001), but comparable in carriers with or without M-mut when considering separately ENI + GZ (2.84 [0.95/3.89] vs 2.61 [-1.10/4.06] log10 IU/mL, P = 0.330] and CH + CI (3.57 [2.67/4.38] vs 3.63 [2.41/4.92] log10 IU/mL, P = 0.37). Infection phase (β: 0.422, P < 0.001), age (β: -0.260, P < 0.001), ALT (β: -0.103, P = 0.045), liver stiffness (β: -0.118, P = 0.039) and HBV-DNA (β: 0.384, P < 0.001), but not M-mut were independently associated with HBsAg serum levels. CONCLUSIONS: In HBeAg negative, genotype-D, carriers Pre-S/S heterogeneity increases with severity of liver disease, but does not influence HBsAg serum levels, that in low viraemic carriers are associated with an effective control of HBV.
引用
- Cavallone D, Ricco G, Oliveri F, et al. Do the circulating Pre-S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection? Aliment Pharmacol Ther. 2020. PMID: 32390175. doi:10.1111/apt.15753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。